Optimizing Molecular Minimal Residual Disease Analysis in Adult Acute Lymphoblastic Leukemia
Cancers · 06.01.2023 · 15 (2) · 374
DOI: 10.3390/cancers15020374 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 06.01.2023. Verfasst von Irene Della Starza und 9 weiteren Autor:innen. Beteiligte Einrichtung: Hematology, Department of Translational and Precision Medicine, "Sapienza" University, Via Benevento 6, 00161 Rome, Italy. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 127 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Minimal/measurable residual disease (MRD) evaluation has resulted in a fundamental instrument to guide patient management in acute lymphoblastic leukemia (ALL). From a methodological standpoint, MRD is defined as any approach aimed at detecting and possibly quantifying residual neoplastic cells beyond the sensitivity level of cytomorphology. The molecular methods to study MRD in ALL are polymerase chain reaction (PCR) amplification-based approaches and are the most standardized techniques. However, there are some limitations, and emerging technologies, such as digital droplet PCR (ddPCR) and next-generation sequencing (NGS), seem to have advantages that could improve MRD analysis in ALL patients. Furthermore, other blood components, namely cell-free DNA (cfDNA), appear promising and are also being investigated for their potential role in monitoring tumor burden and response to treatment in hematologic malignancies. Based on the review of the literature and on our own data, we hereby discuss how emerging molecular technologies are helping to refine the molecular monitoring of MRD in ALL and may help to overcome some of the limitations of standard approaches, providing a benefit for the care of patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Hematology, Department of Translational and Precision Medicine, "Sapienza" University, Via Benevento 6, 00161 Rome, Italy.
- GIMEMA Foundation, 00182 Rome, Italy.
ORCID-Profile: Irene Della Starza, Vittorio Bellomarino, Roberta Soscia
Zitieren
APA
Della Starza, I., De Novi, L. A., Elia, L., Bellomarino, V., Beldinanzi, M., Soscia, R., Cardinali, D., Chiaretti, S., Guarini, A., & Foà, R. (2023). Optimizing Molecular Minimal Residual Disease Analysis in Adult Acute Lymphoblastic Leukemia. Cancers, 15(2), 374. https://doi.org/10.3390/cancers15020374
Vancouver
Della Starza I, De Novi LA, Elia L, Bellomarino V, Beldinanzi M, Soscia R, et al. Optimizing Molecular Minimal Residual Disease Analysis in Adult Acute Lymphoblastic Leukemia. Cancers. 2023;15(2):374. doi:10.3390/cancers15020374
BibTeX
@article{DellaStarza2023,
author = {Della Starza, Irene and De Novi, Lucia Anna and Elia, Loredana and Bellomarino, Vittorio and Beldinanzi, Marco and Soscia, Roberta and Cardinali, Deborah and Chiaretti, Sabina and Guarini, Anna and Foà, Robin},
title = {Optimizing Molecular Minimal Residual Disease Analysis in Adult Acute Lymphoblastic Leukemia},
journal = {Cancers},
year = {2023},
volume = {15},
number = {2},
pages = {374},
doi = {10.3390/cancers15020374}
}
EUVIMED